

Date: July 07, 2025

BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400001 Scrip Code: 544292, ISIN: INE013P01021	National Stock Exchange of India Ltd Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E) Mumbai – 400051 Symbol: ONESOURCE
--	--

Dear Sir/ Madam,

Sub: Intimation under Regulation 30 of Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015: Appointment of Senior Managerial Personnel

Pursuant to Regulation 30 (read with Part A of Schedule III) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that the Board of Directors (“Board”) of the Company, has considered and approved the appointment of Mr. Jeffrey Wong, as the Chief Business Officer (CBO) of the Company, effective from July 07, 2025.

The details required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 are enclosed as **Annexure**.

We request you to take the above on record.

For and on behalf of
OneSource Specialty Pharma Limited

Trisha A
Digitally signed
by Trisha A
Date: 2025.07.07
17:45:06 +05'30'

Trisha A
Company Secretary and Compliance Officer
Membership Number: A47635

Annexure

Sl. No.	Particulars	Details
1.	Reason for change viz. appointment/ re-appointment/ resignation/ removal/ death or otherwise	Appointment of Mr. Jeffrey Wong as the Chief Business Officer (CBO) of the Company.
2.	Date of appointment/ re-appointment / cessation (as applicable) & term of appointment / re-appointment	Effective date of appointment: July 07, 2025 Term of Appointment: Not Applicable
3.	Brief profile (in case of appointment)	Enclosed
4.	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable
5	Disclosures as per NSE/CML/2018/24 dated June 20, 2018 and BSE Circular BSE circular no. LIST/COMP/14/2018-19, dated June 20, 2018.	Not Applicable

Brief Profile: Jeffrey Wong

Jeffrey Wong is a distinguished global commercial executive with over 30 years of experience driving innovation and growth across the biopharmaceutical industry. His career spans leadership in bioprocess products and CDMO services, supporting mammalian, microbial and cell and gene therapy platforms.

Jeff began his journey contributing to the Human Genome Project, where he helped pioneer next-generation DNA and protein sequencing technologies—cornerstones of today’s biologic therapeutics. He later transitioned into biologics manufacturing, playing pivotal roles in regulatory filings and leading FDA approvals for therapies including Viadur and Zenapax.

His most recent role was as Head of Biologics at Syngene International.

Over the course of his career, Jeff has held senior leadership positions at Fujifilm Diosynth Biotechnologies, Thermo Fisher Scientific, Sartorius Stedim Biotech, and other leading organizations. He has spearheaded global strategic partnerships, negotiated multi-year commercial agreements, and consistently delivered commercial growth through strategic deal-making and alliance development.

Known for his customer-first mindset and collaborative leadership style, Jeff excels at building high-performing commercial teams across geographies. He is deeply committed to mentoring emerging leaders, fostering inclusive and diverse teams, and delivering tailored solutions that enable biopharma clients to scale innovation from development through commercialization.